Founder leaves Curavec for health reasons

Alongside Biontech, Curevac was actually the great German hope in the fight against the coronavirus pandemic. However, its drug disappointed in an efficacy test. Now founder Ingmar Hoerr and another member of the Supervisory Board are apparently leaving the company.

The bad news at Curavec doesn't seem to stop: After the company announced last week that, at this stage, the corona vaccine it has developed is only 47 percent effective, founder Ingmar Hoerr is leaving Curavec for good, according to a report. He founded the company in 2000 and left last year after suffering a brain haemorrhage. A spokesperson for Curavec has now announced that Hoerr will not be standing for the Supervisory Board again for health reasons.

This is not the only personnel change: Timothy M. Wright has been a member of the Supervisory Board since 2019 and, according to a report in Manager Magazin, is now leaving Curavec to pursue his own professional interests. At the time, he had been brought into the company primarily to support the mRNA technology on which Curavec's coronavirus vaccine is now based.

Last week, the company published the interim results of a study on the efficacy of its coronavirus vaccine, which was only 47%. As a result, the company's share price fell by half at times. After Biontech, Curevac is the second German company to develop a vaccine using mRNA technology.